COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,536 Articles (22,881 medRxiv, 8,655 bioRxiv)

Most recent first Previous |  Page 730: Articles 7291-7300  | Next

Vitamin C is an efficient natural product for prevention of SARS-CoV-2 infection by targeting ACE2 in both cell and in vivo mouse models
Zuo, Y., Zheng, Z., Huang, Y., He, J., Zang, L., Ren, T., Cao, X., Miao, Y., Yuan, Y., Liu, Y., Ma, F., Tian, S., Dai, J., Ding, Q., Zheng, H.
10.1101/2022.07.14.499651 — Posted: 2022-07-15
A zebrafish model of COVID-19-associated cytokine storm syndrome reveals that the Spike protein signals via TLR2
Tyrkalska, S. D., Martinez-Lopez, A., Pedoto, A., Candel, S., Cayuela, M. L., Mulero, V.
10.1101/2022.07.14.500031 — Posted: 2022-07-15
Ending transmission of SARS-CoV-2: sterilizing immunity using an intranasal subunit vaccine
Leekha, A., Saeedi, A., Sefat, S. R., Kumar, M., Paniagua, M. M., Damian, A., Kulkarni, R., Rezvan, A., Mosoumi, S., Liu, X., Cooper, L. J. N., Sebastian, M., Hurst, B. L., Varadarajan, N.
10.1101/2022.07.14.500068 — Posted: 2022-07-15
SARS-CoV-2 BA.4 infection triggers more cross-reactive neutralizing antibodies than BA.1
Richardson, S., Motlou, T., van der Mescht, M., Lambson, B., Everatt, J., Amoako, D., Van Gottberg, A., Wolter, N., de Beer, Z., Roma de Villiers, T., Bodenstein, A., van den Berg, G., Rossouw, T. M., Boswell, M., Ueckermann, V., Bhiman, J., Moore, P.
10.1101/2022.07.14.500039 — Posted: 2022-07-15
Fc effector activity and neutralization against SARS-CoV-2 BA.4 is compromised in convalescent sera, regardless of the infecting variant
Richardson, S., Kgagudi, P., Manamela, N. P., Kaldine, H., Venter, E., Pillay, T., Lambson, B. E., van der Mescht, M., Hermanus, T., de Beer, Z., de Villier, T., Bodenstein, A., van den Berg, G., du Pisanie, M., Burgers, W., Ntusi, N. A. B., Ueckermann, V., Rossouw, T., Boswell, M., Moore, P.
10.1101/2022.07.14.500042 — Posted: 2022-07-15
Practical application of CO2 as an indicator regarding the risk of infection
Hartmann, A., Cetin, Y. E., Gastmeier, P., Kriegel, M.
10.1101/2022.07.14.22277631 — Posted: 2022-07-15
Sudden hearing loss following vaccination against COVID-19
Nieminen, T., Kivekas, I., Artama, M., Nohynek, H., Kujansivu, J., Hovi, P.
10.1101/2022.07.10.22277380 — Posted: 2022-07-15
Factors Associated with COVID-19 Breakthrough Infection in the Pre-Omicron Era Among Vaccinated Patients with Rheumatic Diseases: A Cohort Study
Patel, N. J., Wang, X., Fu, X., Kawano, Y., Cook, C., Vanni, K. M., Qiann, G., Banasiak, E., Kowalski, E., Zhang, Y., Sparks, J. A., Wallace, Z. S.
10.1101/2022.07.13.22277606 — Posted: 2022-07-15
Bayesian Shrinkage Priors in Zero-Inflated and Negative Binomial Regression models with Real World Data Applications of COVID-19 Vaccine, and RNA-Seq
Bhattacharyya, A., mitra, r., Rai, S., Pal, S.
10.1101/2022.07.13.22277610 — Posted: 2022-07-15
Assessing Risk Exposure of COVID-19 in Indonesian Government-owned Public Health Center Physicians
Suryatma, A., Purnamasari, T., Hendarwan, H.
10.1101/2022.07.13.22277613 — Posted: 2022-07-15

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).